Profusa, Inc. $(PFSA)$, a digital health company specializing in continuous biochemical monitoring technology, has announced a Letter of Intent to establish a distribution agreement in Spain for its Lumee Oxygen platform. The agreement is with Dismeval, S.L., a Spanish distributor known for its expertise in medical and surgical equipment across Spain, including the Canary and Balearic Islands. This partnership represents Profusa's initial steps towards building a strong distribution network in Europe. The company aims to introduce its innovative real-time personal healthcare technologies to the clinical community, targeting a $10.5 billion global market for its tissue oxygen technology. This market includes applications in peripheral artery disease, chronic wounds, and critical limb ischemia, addressing a significant clinical need in Europe with over 300,000 endovascular procedures annually.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。